X

Trial Profile

Peptide Targets for Glioblastoma Against Novel Cytomegalovirus Antigens

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Jun 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PEPIDH1M (Primary) ; Diphtheria-tetanus vaccine; Montanide ISA-51; Temozolomide
Indications Glioblastoma
Focus Adverse reactions; Pharmacodynamics
Acronyms PERFORMANCE

Most Recent Events

12 Oct 2021 Number of treatment arms has been increased from 2 to 5, by the addition of Experimental: 5-day TMZ: Components A and B, Experimental: 21-day TMZ: Components A and B and Experimental: 5-day TMZ: Safety Cohort arms.
12 Oct 2021 Status changed from active, no longer recruiting to discontinued due to lack of funds.
24 Nov 2020 Planned End Date changed from 1 Jun 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com